Novel surface modified solid lipid nanoparticles as intranasal carriers for ropinirole hydrochloride: application of factorial design approach

References

• Abdelwahed W, Degobert G, Stainmesse S, Fessi H. (2006). Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev 58:1688–713
   PubMed Web of Science ®Google Scholar
• Belgamwar VS, Patel HS, Joshi AS, et al. (2011). Design and development of nasal mucoadhesive microspheres containing tramadol HCl for CNS targeting. Drug Deliv 18:353–60
   PubMed Web of Science ®Google Scholar
• Chalikwar SS, Belgamwar VS, Talele VR, et al. (2012). Formulation and evaluation of Nimodipine-loaded solid lipid nanoparticles delivered via lymphatic transport system. Colloids Surf B: Biointerfaces 97:109–16
   PubMed Web of Science ®Google Scholar
• Fukuzaki K, Kamenosono T, Nagata R. (2000). Effects of ropinirole on various Parkinsonian models in mice, rats, and cynomolgus monkeys. Pharmacol Biochem Behav 65:503–8
   PubMed Web of Science ®Google Scholar
• Heurtault B, Saulnier P, Pech B, et al. (2003). Physico-chemical stability of colloidal lipid particles. Biomaterials 24:4283–300
   PubMed Web of Science ®Google Scholar
• Hurley MJ, Jenner P. (2006). What has been learnt from study of dopamine receptors in Parkinson's disease? Pharmacol Ther 111:715–28
   PubMed Web of Science ®Google Scholar
• Illum L. (2000). Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 11:1–18
   PubMed Web of Science ®Google Scholar
• Jain SA, Chauk DS, Mahajan HS, et al. (2009). Formulation and evaluation of nasal mucoadhesive microspheres of Sumatriptan succinate. J Microencapsul 26:711–21
   PubMed Web of Science ®Google Scholar
• Lee PI. (1985). Kinetics of drug release from hydrogel matrices. J Control Release 2:277–88
   Google Scholar
• Mahajan HS, Tatiya BV, Nerkar PP. (2012). Ondansetron loaded pectin based microspheres for nasal administration: in vitro and in vivo studies. Powder Technol 221:168–76
   Web of Science ®Google Scholar
• Mehnert W, Mader K. (2001). Solid lipid nanoparticles Production, characterization and applications. Adv Drug Deliv Rev 47:165–96
   PubMed Web of Science ®Google Scholar
• Mistry A, Stolnik S, Illum L. (2009). Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 379:146–57
   PubMed Web of Science ®Google Scholar
• Motwani SK, Chopra S, Talegaonkar S, et al. (2007). Chitosan–sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimization and in vitro characterisation. Eur J Pharm Biopharm 68:513–25
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Ray S, Thakur RS. (2009). Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Ind J Pharm Sci 71:349–58
   PubMed Web of Science ®Google Scholar
• Paliwal R, Rai S, Vaidya B, et al. (2009). Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomedicine 5:184–91
   PubMed Web of Science ®Google Scholar
• Pardeshi CV, Rajput PV, Belgamwar VS, Tekade AR. (2011). Formulation, optimization and evaluation of spray-dried mucoadhesive microspheres as intranasal carriers for Valsartan. J Microencapsul 29:103–14
   PubMed Web of Science ®Google Scholar
• Patel S, Chavhan S, Soni H, et al. (2011). Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route. J Drug Target 19:468–74
   PubMed Web of Science ®Google Scholar
• Rudra A, Rudra P, Chatterjee S, et al. (2007). Parkinson’s diseases and Anaesthesia. Ind J Anaesthesia 51:382–8
   Google Scholar
• Salawu F, Olokoba A, Danburam A. (2010). Current management of Parkinson’s disease. Ann Afr Med 9:55–61
   PubMedGoogle Scholar
• Shegokar R, Singh KK, Muller RH. (2010). Production & stability of stavudine solid lipid nanoparticles – from lab to industrial scale. Int J Pharm. 416:461–70
   PubMedGoogle Scholar
• Tan SW, Billa N, Roberts CR, Berley JC. (2010). Surfactant effects on the physical characteristics of Amphotericin B-containing nanostructured lipid carriers. Colloids Surf A: Physicochem Eng Asp 372:73–9
   Web of Science ®Google Scholar
• Tas C, Ozkan CK, Savaser A, et al. (2006). Nasal absorption of metoclopramide from different Carbopol 981 based formulations: in vitro, ex vivo and in vivo evaluation. Eur J Pharm Biopharm 64:246–54
   PubMed Web of Science ®Google Scholar
• Trotta M, Debernardi F, Caputo O. (2003). Preparation of solid lipid nanoparticles by a solvent emulsification–diffusion technique. Int J Pharm 257:153–60
   PubMed Web of Science ®Google Scholar
• Varshosaz J, Tabbakhian M, Mohammadi MY. (2010). Formulation and optimization of solid lipid nanoparticles of buspirone HCl for enhancement of its oral bioavailability. J Liposome Res 20:286–96
   PubMed Web of Science ®Google Scholar
• Venkateswarlu V, Manjunath K. (2004). Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release 95:627–38
   PubMed Web of Science ®Google Scholar
• Vogel HG, ed. (2002). Psychotropic and neurotropic activity. In: Drug discovery and evaluation: pharmacological assays. 2nd ed. New York (NY): Springer, 577–81
   Google Scholar
• Wang Q, Gong T, Sun X, Zhang Z. (2011). Structural characterization of novel phospholipid lipid nanoparticles for controlled drug delivery. Colloids Surf B: Biointerfaces 84:406–12
   PubMed Web of Science ®Google Scholar
• Zhang X, Liu J, Qiao H, et al. (2010). Formulation optimization of dihydroartemisinin nanostructured lipid carrier using response surface methodology. Powder Technol 197:120–8
   Web of Science ®Google Scholar